NXTC Q1 2022 Earnings — NextCure, Inc. Revenue & Financial Results | Market Cap Arena

NXTCNextCure, Inc.

$36M

Q1 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$21M

Net Income

-$21M

EPS (Diluted)

$-8.92

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$15M

Free Cash Flow

-$16M

Stock-Based Comp.

$3M

Balance Sheet

Total Assets

$223M

Total Liabilities

$9M

Stockholders' Equity

$214M

Cash & Equivalents

$11M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	$0	—
Operating Income	-$21M	-$17M	-20.5%
Net Income	-$21M	-$17M	-24.6%